Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer

Jan 26 2018

• By Mandy Jackson

US-Money-and-Pills_V2_1200x675

Related Content

Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Jan 25 2017

Celgene Eyes IO Growth With BeiGene China Pact

Jul 06 2017

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Jan 09 2018

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort

Dec 20 2016

Celgene diversifies with $7.2bn Receptos buy

Jul 15 2015

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Nov 21 2017

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Oct 20 2017

Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence

Oct 27 2017

What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib

Oct 13 2017

Related Companies

Bristol Myers Squibb Company

Impact Biomedicines, Inc.

Bristol Myers Squibb Company

BeOne Medicines Ltd.

Receptos, Inc.

Genetix Biotherapeutics

Acceleron Pharma, Inc.

Additional Topics

Sales & Earnings Business Strategies Deals M & A Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window